Novartis’ kidney disease drug Fabhalta receives US FDA approval EP News Bureau Aug 8, 2024 Fabhalta specifically targets the alternative complement pathway of the immune system. When overly activated in the kidneys, the…
IGNAZ trial interim results highlight HI-Bio’s potential to differentiate in IgAN space: GlobalData GlobalData May 31, 2024 According to the results, the use of MOR-202 (felzartamab) demonstrated a deep and durable reduction in proteinuria in patients…
